Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb (BMY) closed at $60.16 in the latest trading session, marking a -1.26% move from the prior day.

Bristol-Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know

AbbVie

Fortinet

Eli Lilly

NVIDIA

Investing in ESG stocks bear lesser financial risks due to their focus on environment, employees and supply chain. They proved resilient during the coronavirus pandemic and will continue to surge.

ESG Investing Trend to Stay Strong Post Pandemic: 5 Top Picks

Pfizer

Bristol Myers Squibb and Pfizer are two of the safest stocks investors can buy right now.

2 Top Pharma Stocks to Buy in June

Madrigal Pharmaceuticals

Vertex Pharmaceuticals

They have one big thing in common: great growth prospects.

3 Top Biotech Stocks to Buy in June

Bristol-Myers (BMY) reported earnings 30 days ago. What's next for the stock?

Bristol-Myers (BMY) Up 0.5% Since Last Earnings Report: Can It Continue?

Bank of America

Look no further for attractive valuations, solid businesses, and great growth prospects.

3 Dirt-Cheap Stocks You Simply Shouldn't Ignore

Gilead Sciences

Which of these household names is the better buy?

Better Buy: Bristol Myers Squibb vs. Gilead Sciences

Bristol Myers' (BMY) late-stage study of Zeposia in patients with moderate-to-severe ulcerative colitis meets both its main goals.

Bristol Myers' Zeposia Meet Goals in Ulcerative Colitis Study

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes?

Why Bristol-Myers Squibb (BMY) is a Top Dividend Stock for Your Portfolio

Novo Nordisk

Sanofi

Takeda Pharmaceutical

Zoetis

Pharmaceutical stocks dipped by a single-digit percentage in the first five months of 2020, trailing their biotech brethren. Still, there are standout companies in the group.

Why These 5 Pharma Stocks Are Outplaying 90% Of The Stock Market

Bristol Myers Squibb reported positive ulcerative colitis treatment data Tuesday helping shares of rival Arena Pharmaceuticals to pop. Arena is testing a similar drug called etrasimod.

Why Bristol Myers' Success In Ulcerative Colitis Sent Arena Stock Flying

Shares of Bristol-Myers Squibb Inc. BMY, +0.95% gained 1.2% in premarket trading on Tuesday after the drugmaker said Zeposia met both primary goals in a late-stage clinical trial for colitis.

Bristol-Myers Squibb's stock rises on Zeposia trial findings, launch in the U.S.

Bristol-Myers Squibb Co. (NYSE:BMY) recently reported first-quarter earnings that easily beat analysts’ estimates for revenue and earnings per share.

Bristol-Myers Deserves Better Than a Single-Digit Multiple

Bristol-Myers Squibb (BMY) closed at $59.72 in the latest trading session, marking a -0.15% move from the prior day.

Bristol-Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know

Bristol-Myers (BMY) possesses solid growth attributes, which could help it handily outperform the market.

Is Bristol-Myers (BMY) a Solid Growth Stock? 3 Reasons to Think " Yes "

The stock price for Bristol-Myers Squibb is up by roughly 15% in the last few years (since Jan 2017), driven by the company’s increased market share in the anticoagulants market. In comparison, Pfizer, one of the largest U.S.

Is Pfizer’s 2x Price Rise Versus Bristol-Myers Squibb Justified?

Bristol-Myers (BMY) gets EC nod for Zeposia for the treatment of adult patients with relapsing remitting multiple sclerosis.

Bristol-Myers (BMY) Wins EC Approval for MS Drug Zeposia

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy Bristol-Myers Squibb (BMY) Stock?

Biopharma companies are among the most resilient among sectors during the coronavirus pandemic, and one large-cap biopharma has a slew of products in its pipeline that have blockbuster potential, according to BofA Securities.

Bristol-Myers Analyst Says 'Big 7' Pipeline Assets Hold $15B In Peak Sales Potential

Applied Materials

MarketAxess Holdings

Newmont Mining

ServiceNow

In the latest market rally driven by hopes surrounding potential coronavirus vaccines and reopening of the economy, the S&P 500 reclaimed its 3,000 level and is poised to rise further.

S&P Reclaims 3,000: Buy 6 Stocks With More Than 25% Growth

Don't Gamble In The Markets, Look At These 2 Blue Chip Healthcare Names Instead

Neurocrine Biosciences

QuidelOrtho Corp

Teladoc

Tandem Diabetes Care

Several top health care stocks are in buy zones or setting up, including Teladoc and Neurocrine Biosciences. They are all worth adding to your watchlist.

Teladoc, Bristol Myers, Quidel, Neurocrine Bio, Tandem Diabetes: 5 Health Stocks To Monitor Closely

B2Gold

Chembio Diagnostics

Earnings yield has an edge over P/E ratio as it can be used to compare a stock with not just other stocks but also with fixed income securities.

These 4 High Earnings Yield Stocks are Hot Investment Picks

Bristol Myers Squibb strengthened its oncology lineup thanks to its acquisition of Celgene, but how well will the pharma giant perform moving forward?

Could This Cancer Drug Developer’s Stock Make You Filthy Rich?

Bristol-Myers Squibb’s stock (NYSE: BMY) has significantly outperformed the broader markets as well as some of its peers over the last few weeks. While Bristol-Myers Squibb’s stock grew 38% since the recent lows of March 23, the S&P 500 gained 28%.

News for Bristol-Myers Stock (BMY)